Please provide your email address to receive an email when new articles are posted on . NEW ORLEANS — Treatment with combination ezetimibe and simvastatin plus extended-release niacin may aid patients ...
A Swedish database of over 35,000 individuals found better cardiovascular outcomes when ezetimibe was added earlier to statin therapy for secondary prevention. Study authors deemed ezetimibe a ...
— Bempedoic Acid / Ezetimibe Combination Tablet Achieved Robust 40% Placebo Corrected LDL-C Lowering —— Provided 25% hsCRP Reduction —— No Worsening of Glycemic Control —— Overall Adverse Events ...
Hosted on MSN
Rethinking combo therapy for heart health
New research suggests that pairing a moderate-intensity statin with ezetimibe can match the cardiovascular benefits of high-intensity statins while reducing the likelihood of developing type 2 ...
MAASTRICHT, the Netherlands—Use of a fixed-dose combination of bempedoic acid and ezetimibe in statin-treated patients at high risk for cardiovascular disease significantly lowers LDL cholesterol ...
Cardiovascular diseases represent the most common cause of death worldwide. According to the World Health Organization (WHO), around 17.9 million deaths occur due to the cardiovascular diseases each ...
A combination tablet containing the cholesterol-lowering drugs ezetimibe and atorvastatin is back on the path to possible FDA approval, according to Merck, which already markets Zetia (ezetimibe) and ...
MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Europe GMbH (hereafter, ‘Daiichi Sankyo’) today announced positive initial results from the 12-week Phase 2 bempedoic acid / ezetimibe fixed dose combination ...
WHITEHOUSE STATION, New Jersey — Merck has resubmitted a new drug application (NDA) for the combination atorvastatin and ezetimibe (Zetia) tablet to the US Food and Drug Administration (FDA). Back in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results